Meet the Team

Management

 

Nancy Chang

Nancy T. Chang, Ph.D. has served as a Director at Ansun since 2011. Since 2007, Dr. Chang has served as the President of Apex Enterprises, Inc., an investment management company with a major focus on healthcare investments. From 2007 to 2012, she was the Chairperson and Senior Managing Director of Caduceus Asia Partners at OrbiMed Advisors L.L.C. From 1987 to 2007, Dr. Chang served as Co-Founder, President and Chairman of Tanox, Inc., which was sold to Genentech in 2007. Prior to founding Tanox, Dr. Chang held several leadership positions at Centocor, now a division of Johnson & Johnson. She was also an Associate Professor at Baylor College of Medicine, and before that, she worked at the Roche Institute of Molecular Biology. She has served on the boards of a number of companies, including Charles River Laboratories International, Inc., Applied Optoelectronics Inc. and is currently a member of the board of directors of SciClone Pharmaceuticals, Inc. In addition, Dr. Chang was a member of the board of directors at the Biotechnology Industry Organization (BIO) and BioHouston. Dr. Chang also was a Director at the Federal Reserve Bank in the Dallas Houston Branch, and was a Director for Project Hope. She has published more than 35 papers on topics ranging from monoclonal antibodies to HIV and holds seven patents. Dr. Chang received her Doctorate in Biological Chemistry from Harvard University.

Mark Attebury

MarkA_photoMark Attebury, Vice President of Finance, joined Ansun Biopharma as the Director of Finance in November 2014.  Prior to joining Ansun, Mark was Associate Director of Finance for Amylin Pharmaceuticals, a publicly traded company specializing in diabetes and metabolic disorders, supporting early and mid-stage programs.  Prior to Amylin, Mark was FP&A Manager for a San Diego based division of Boston Scientific, a publicly traded medical device manufacturer, making specialty cardiac angioplasty balloons.  Mark started his career in the banking industry in both large and small sized institutions.  Mark received a BA in Economics and an MBA, both from San Diego State University.

 

 

Mike Havluciyan

1be99c_fc6ebb2432c042c6b5beeab36890fc94.jpg_srz_p_103_135_75_22_0.50_1.20_0Mike Havluciyan has served as our V.P., General Counsel since October 2011, and before that, served as our Assistant V.P. of Legal and Business Affairs beginning in April 2009.  Prior to Ansun, Mr. Havluciyan initially served as Director of Intellectual Property at Nanogen, Inc. and was subsequently promoted to Associate General Counsel.  From 1998-2006, he was an associate first at Lyon & Lyon and then Fish & Richardson, specializing in intellectual property law, with a particular emphasis on patent litigation, patent prosecution and IP counseling for life science companies.  Mr. Havluciyan received a B.S. in Biology from the University of California, Irvine and his law degree from Loyola Law School, where he was a Note and Comment Editor and published author on the Loyola of Los Angeles Entertainment Law Journal.  Mr. Havluciyan has been a member of the California Bar since 1998.

 

Board of Directors


Allen Chao

Allen Chao, Ph.D. has served as a Director at Ansun since 2010.  Since January 2008, Dr. Chao has been Chairman of Newport Healthcare Advisors, LLC, a healthcare investment management and consulting company.  Dr. Chao was a co-founder of Watson Pharmaceuticals, Inc. (now Actavis plc), a specialty pharmaceutical company, serving as a director from 1985 to May 2008, Chairman of the board of directors from May 1996 to May 2008, and Chief Executive Officer from 1985 to September 2007. While at Watson, Dr. Chao oversaw the company’s growth, through internal R&D, licensing and acquisitions of pharmaceutical products and technologies, as well as mergers and acquisition activities. Dr. Chao received a Ph.D. in industrial and physical pharmacy from Purdue University in 1973. In May of 2000, he received the degree of Doctor of Science from Purdue.

Nancy Chang

Nancy T. Chang, Ph.D. has served as a Director at Ansun since 2011. Since 2007, Dr. Chang has served as the President of Apex Enterprises, Inc., an investment management company with a major focus on healthcare investments. From 2007 to 2012, she was the Chairperson and Senior Managing Director of Caduceus Asia Partners at OrbiMed Advisors L.L.C. From 1987 to 2007, Dr. Chang served as Co-Founder, President and Chairman of Tanox, Inc., which was sold to Genentech in 2007. Prior to founding Tanox, Dr. Chang held several leadership positions at Centocor, now a division of Johnson & Johnson. She was also an Associate Professor at Baylor College of Medicine, and before that, she worked at the Roche Institute of Molecular Biology. She has served on the boards of a number of companies, including Charles River Laboratories International, Inc., Applied Optoelectronics Inc. and is currently a member of the board of directors of SciClone Pharmaceuticals, Inc. In addition, Dr. Chang was a member of the board of directors at the Biotechnology Industry Organization (BIO) and BioHouston. Dr. Chang also was a Director at the Federal Reserve Bank in the Dallas Houston Branch, and was a Director for Project Hope. She has published more than 35 papers on topics ranging from monoclonal antibodies to HIV and holds seven patents. Dr. Chang received her Doctorate in Biological Chemistry from Harvard University.

Michael Chang

Dr. Michael Chang – Chairman of OBI, also the director Amaran as well as the founder of both Optimer Pharmaceuticals and OBI. In 1994, Dr. Chang
established Pharmanex, a health products company, which was acquired by NuSkin Enterprises, where he was appointed Chief Scientific Advisor.
Prior to this, he founded Cinogen in 1993. Dr. Chang was formerly the Director of Medical Chemistry at Rhone-Poulenc Rorer and Deputy Director
of Medicinal Chemistry at Merck, Sharpe & Dohme (US Merck). Dr. Chang received his Ph.D. in Organic Chemistry from Brandeis University, and
conducted postdoctoral research at MIT. He received his BS in Chemistry from Fu Jen Catholic University in Taiwan. He holds 39 patents and has
published more than 69 scientific papers in peer reviewed journals.